Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity

Yu et al. show that isotype switching can convert clinically relevant anti-CD40 antagonistic antibodies to potent FcγR-independent agonists. The converted antibodies can elicit strong antitumor responses in mouse models.

from Cancer Cell https://ift.tt/3bPWIIK